| Patients n (%) | HIF-2 alpha expression | P value | ||
---|---|---|---|---|---|
 |  | negative | low | high |  |
ABCG2 expression | Â | Â | Â | Â | 0.001* |
   negative | 26 | 8 | 17 | 1 |  |
   low | 97 | 12 | 58 | 27 |  |
   high | 73 | 5 | 39 | 29 |  |
Age | Â | Â | Â | Â | 0.053 |
   ≤ 50 years | 80 | 10 | 54 | 16 |  |
   > 50 years | 116 | 15 | 60 | 41 |  |
Histology-type | Â | Â | Â | Â | 0.285 |
   IDC | 155 | 22 | 86 | 47 |  |
   IDC with others | 41 | 3 | 28 | 10 |  |
Histology-grade | Â | Â | Â | Â | 0.029* |
   G1/G2 | 143 | 16 | 78 | 49 |  |
   G3 | 53 | 9 | 36 | 8 |  |
Tumour size | Â | Â | Â | Â | 0.601 |
   ≤2.0 cm | 97 | 13 | 53 | 31 |  |
   > 2.0 cm | 99 | 12 | 61 | 26 |  |
LNM | Â | Â | Â | Â | 0.808 |
   - | 103 | 13 | 58 | 32 |  |
   + | 93 | 12 | 56 | 25 |  |
ER | Â | Â | Â | Â | 0.544 |
   -/+ | 96 | 10 | 59 | 27 |  |
   ++/+++ | 100 | 15 | 55 | 30 |  |
PR | Â | Â | Â | Â | 0.343 |
   -/+ | 128 | 14 | 79 | 35 |  |
   ++/+++ | 68 | 11 | 35 | 22 |  |
HER2 | Â | Â | Â | Â | 0.923 |
   -/+ | 138 | 18 | 81 | 39 |  |
   ++/+++ | 58 | 7 | 33 | 18 |  |
Ki67 | Â | Â | Â | Â | 0.043* |
   Positive ≤50% | 154 | 20 | 83 | 51 |  |
   Positive > 50% | 42 | 5 | 31 | 6 |  |
Clinical stage | Â | Â | Â | Â | 0.538 |
   Stage I | 60 | 7 | 33 | 20 |  |
   Stage IIa and IIb | 86 | 13 | 47 | 26 |  |
   StageIIIa and IIIb | 50 | 5 | 34 | 11 |  |